Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 152 results for multiple sclerosis

  1. ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)

    NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot

  2. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 [TSID11778]

    Topic prioritisation

  3. Faecal incontinence in adults: management (CG49)

    This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis. It aims to improve the physical and mental health and quality of life of people with faecal incontinence.

  4. NICE recommends new treatment option for highly active multiple sclerosis

    Thousands of people living with a form of multiple sclerosis (MS) will benefit from greater treatment choice, following new guidance from NICE.

  5. NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses the best available evidence (including experience to date from the risk-sharing scheme) and includes all currently available treatments.

    TA254/2 Question NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses...

  6. Multiple long-term conditions: medication review (IND207)

    This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186

  7. Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)

    This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management.

  8. NICE visualisation of treatment options incorporating technology appraisals: interim process guide (PMG38)

    This process guide explains how treatment option summaries for multiple guidelines were developed in an open, transparent, and timely way, with appropriate expert input

  9. Stereotactic radiosurgery for trigeminal neuralgia (IPG715)

    Evidence-based recommendations on stereotactic radiosurgery for trigeminal neuralgia in adults. This involves focusing radiation on the trigeminal nerve to damage it, thereby relieving pain.

  10. Rehabilitation for chronic neurological disorders including acquired brain injury (NG252)

    This guideline covers rehabilitation in all settings for children, young people and adults with a chronic neurological disorder, neurological impairment or disabling neurological symptoms due to acquired brain injury, acquired spinal cord injury, acquired peripheral nerve disorder, functional neurological disorder or progressive neurological disease.

  11. Multiple sclerosis - sativex [ID387]

    Discontinued Reference number: GID-TAG368

  12. QTUG for assessing falls risk and frailty (MIB73)

    NICE has developed a medtech innovation briefing (MIB) on the Quantitative Timed Up and Go (QTUG)

  13. Biotin for treating primary and secondary progressive multiple sclerosis [ID919]

    Discontinued Reference number: GID-TA10099

  14. Laquinimod for treating relapsing-remitting multiple sclerosis [ID560]

    Discontinued Reference number: GID-TAG337

  15. Past appeals and decisions

    Past technology appraisal appeals and decisions